0001708599-25-000130.txt : 20251112 0001708599-25-000130.hdr.sgml : 20251112 20251112123654 ACCESSION NUMBER: 0001708599-25-000130 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20251107 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251112 DATE AS OF CHANGE: 20251112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Serina Therapeutics, Inc. CENTRAL INDEX KEY: 0001708599 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 821436829 STATE OF INCORPORATION: AL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38519 FILM NUMBER: 251471118 BUSINESS ADDRESS: STREET 1: 601 GENOME WAY STREET 2: SUITE 2001 CITY: HUNTSVILLE STATE: AL ZIP: 35806 BUSINESS PHONE: (256) 327-9630 MAIL ADDRESS: STREET 1: 601 GENOME WAY STREET 2: SUITE 2001 CITY: HUNTSVILLE STATE: AL ZIP: 35806 FORMER COMPANY: FORMER CONFORMED NAME: AgeX Therapeutics, Inc. DATE OF NAME CHANGE: 20170606 8-K 1 ser-20251107.htm 8-K ser-20251107
0001708599false00017085992025-11-072025-11-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 7, 2025
Serina Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware1-3851982-1436829
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)
601 Genome Way, Suite 2001
Huntsville, Alabama 35806
(Address of principal executive offices)
(256) 327-9630
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered
Common Stock, par value $0.0001 per shareSERNYSE American
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.07 Submission of Matters to a Vote of Security Holders.

The Board of Directors of Serina Therapeutics, Inc. (the “Company”) held the Company’s 2025 Annual Meeting of the Stockholders (the “Annual Meeting”) on November 7, 2025. A quorum was present at the meeting. The final results of voting for each matter submitted to a vote of stockholders at the Annual Meeting are set forth below.

Proposal 1
Election of Two Directors

Voting results for the election of directors were as follows:
Nominees
For
Withheld
Broker Non-Votes
Steve Ledger
4,165,885
93,287
2,681,141
Karen J. Wilson
4,169,893
89,279
2,681,141

Accordingly, both of the Company’s nominees were elected to serve as directors of the Company until the 2028 Annual Meeting of Stockholders or until their respective successors are appointed, elected and qualified.

Proposal 2
Ratification of the Appointment of Auditors

Ratification of the appointment of Frazier & Deeter, LLC as the Company’s independent registered public accounting firm for the 2025 fiscal year was approved by the following vote:

For
Against
Abstain
Broker Non-Votes
6,544,850
377,827
17,636
—

Proposal 3
Approval of the Convertible Note and Warrants Proposal

As described in the Company’s Proxy Statement, the issuance of common stock in connection with the exercise of the Convertible Note and Warrants was approved by the following vote:

For
Against
Abstain
Broker Non-Votes
4,149,038
108,481
1,653
2,681,141
Item 9.01 - Financial Statements and Exhibits.

(d) Exhibits
Exhibit
Number		Description
104Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SERINA THERAPEUTICS, INC.
Date: November 12, 2025
By:/s/ Steve Ledger
Chief Executive Officer

 EX-101.SCH 2 ser-20251107.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 ser-20251107_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Title of 12(g) Security Title of 12(g) Security Entity Small Business Entity Small Business Entity Interactive Data Current Entity Interactive Data Current Entity Ex Transition Period Entity Ex Transition Period No Trading Symbol Flag No Trading Symbol Flag Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Cover [Abstract] Entity Bankruptcy Proceedings, Reporting Current Entity Bankruptcy Proceedings, Reporting Current Entity Voluntary Filers Entity Voluntary Filers Amendment Flag Amendment Flag Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Pre-commencement Tender Offer Pre-commencement Tender Offer Extension Extension Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, Country Entity Address, Country Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Amendment Description Amendment Description Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Fiscal Year Focus Document Fiscal Year Focus Entity Address, Address Line One Entity Address, Address Line One Other Reporting Standard Item Number Other Reporting Standard Item Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, Address Line Two Entity Address, Address Line Two Document Fiscal Period Focus Document Fiscal Period Focus Document Accounting Standard Document Accounting Standard Title of 12(b) Security Title of 12(b) Security Document Period End Date Document Period End Date Document Period Start Date Document Period Start Date Audited Annual Financial Statements Audited Annual Financial Statements Document Type Document Type Entity Shell Company Entity Shell Company Document Registration Statement Document Registration Statement Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Documents Incorporated by Reference [Text Block] Documents Incorporated by Reference [Text Block] Document Annual Report Document Annual Report Security Exchange Name Security Exchange Name Soliciting Material Soliciting Material Entity Public Float Entity Public Float City Area Code City Area Code Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Entity Primary SIC Number Entity Primary SIC Number Entity Tax Identification Number Entity Tax Identification Number Document Shell Company Report Document Shell Company Report Entity Current Reporting Status Entity Current Reporting Status Document Shell Company Event Date Document Shell Company Event Date Current Fiscal Year End Date Current Fiscal Year End Date Entity Address, State or Province Entity Address, State or Province Written Communications Written Communications Local Phone Number Local Phone Number Country Region Country Region Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Security Reporting Obligation Security Reporting Obligation Entity Filer Category Entity Filer Category Annual Information Form Annual Information Form EX-101.PRE 4 ser-20251107_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.25.3
Cover
Nov. 07, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 07, 2025
Entity File Number 1-38519
Entity Registrant Name Serina Therapeutics, Inc.
Entity Central Index Key 0001708599
Entity Tax Identification Number 82-1436829
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 601 Genome Way
Entity Address, Address Line Two Suite 2001
Entity Address, City or Town Huntsville
Entity Address, State or Province AL
Entity Address, Postal Zip Code 35806
City Area Code (256)
Local Phone Number 327-9630
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol SE
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.3 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://serinatherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ser-20251107.htm ser-20251107.xsd ser-20251107_lab.xml ser-20251107_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ser-20251107.htm": { "nsprefix": "SER", "nsuri": "http://serinatherapeutics.com/20251107", "dts": { "inline": { "local": [ "ser-20251107.htm" ] }, "schema": { "local": [ "ser-20251107.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "labelLink": { "local": [ "ser-20251107_lab.xml" ] }, "presentationLink": { "local": [ "ser-20251107_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://serinatherapeutics.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ser-20251107.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "ser-20251107.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Description", "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Annual Information Form", "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Audited Annual Financial Statements", "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Country Region", "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Accounting Standard", "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period Start Date", "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Registration Statement", "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Shell Company Event Date", "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Shell Company Report", "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference [Text Block]", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Three", "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Bankruptcy Proceedings, Reporting Current", "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Primary SIC Number", "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Extension", "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "No Trading Symbol Flag", "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Other Reporting Standard Item Number", "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(g) Security", "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Reporting Obligation", "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://serinatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0001708599-25-000130-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001708599-25-000130-xbrl.zip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ser-20251107_htm.xml IDEA: XBRL DOCUMENT 0001708599 2025-11-07 2025-11-07 0001708599 false 8-K 2025-11-07 Serina Therapeutics, Inc. DE 1-38519 82-1436829 601 Genome Way Suite 2001 Huntsville AL 35806 (256) 327-9630 false false false false Common Stock, par value $0.0001 per share SE NYSEAMER false